Status:
UNKNOWN
Aribulin Combined With Carboplatin and Bevacizumab in the Treatment of Ovarian Cancer
Lead Sponsor:
Second Affiliated Hospital of Guangzhou Medical University
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
18-75 years
Phase:
PHASE1
PHASE2
Brief Summary
This is a prospective phase II, single-center, single-arm clinical study of platinum-sensitive relapsed ovarian cancer. The main objective of this study is to evaluate the efficacy, safety and tolerab...
Detailed Description
This is a phase II prospective, single-center, single-arm clinical study for platinum-sensitive recurrent ovarian cancer. The main objective of this study is to evaluate the efficacy, safety and toler...
Eligibility Criteria
Inclusion
- Patients with measurable or immeasurable disease (RECIST v1.1) or CA 125 evaluable disease (GCIG criteria) or histologically confirmed diagnosis of recurrent ovarian cancer.
- First disease recurrence after first-line platinum chemotherapy \>6 months.
- 18 years of age ≤75 years of female.
- Expected survival ≥ 3 months.
Exclusion
- Partial tumor related symptoms.
- Partial comorbidity.
- Subjects developed new secondary malignancies.
- other.
Key Trial Info
Start Date :
August 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2025
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT05965141
Start Date
August 1 2023
End Date
June 1 2025
Last Update
July 28 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.